Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

Heijden, Lisa T van der; Nijstad, A. Laura; Uittenboogaard, Aniek; Beijnen, Jos H.; Dorlo, Thomas P. C.; Kaspers, Gertjan J.L.; Huitema, Alwin D. R.

doi:10.1097/ftd.0000000000001090

Therapeutic Drug Monitoring

2023

DOI: 10.1097/ftd.0000000000001090

|View full text |Cite

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

Lisa T van der Heijden

A. Laura Nijstad

Aniek Uittenboogaard

et al.

Abstract: Supplemental Digital Content is Available in the Text.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Uittenboogaard,

van de Velde,

van de Heijden

et al. 2024

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

The low incidence of vincristine‐induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose‐escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.

show abstract

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Uittenboogaard,

van de Velde,

van de Heijden

et al. 2024

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

Abstract: Supplemental Digital Content is Available in the Text.

Cited by 1 publication

References 40 publications

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Contact Info

Product

Resources

About